Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
Royalty Pharma (RPRX) Stock Price & Analysis
711 Followers
RPRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.35 - $33.66
Previous Close$27.27
Volume1.91M
Average Volume (3M)2.74M
Market Cap
$16.29B
Enterprise Value$25.49B
Total Cash (Recent Filing)$495.31M
Total Debt (Recent Filing)$6.14B
Price to Earnings (P/E)15.3
Beta0.71
Next Earnings
Aug 07, 2024EPS Estimate
$0.97Last Dividend Ex-Date
May 16, 2024Dividend Yield2.97%
Share Statistics
EPS (TTM)1.78
Shares Outstanding597,437,271
10 Day Avg. Volume2,726,874
30 Day Avg. Volume2,744,808
Standard Deviation0.06
R-Squared0.14
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.50
Price to Sales (P/S)5.22
Price to Cash Flow (P/CF)5.30
P/FCF Ratio5.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.09
Enterprise Value/Gross Profit10.83
Enterprise Value/Ebitda14.97
Forecast
1Y Price Target
$49.00Price Target Upside79.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Royalty Pharma News
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceRPRX reported results that surpassed forecasts, with earnings per share significantly exceeding expectations.
Future Growth ProspectsAnticipated clinical and regulatory updates in the coming period could serve as a catalyst for positive stock performance.
Share Repurchase ProgramThe company demonstrates financial confidence through its ongoing share repurchase program, with a substantial authorization still available for future buybacks.
Bears Say
Earnings GuidanceAnalyst concerns as the FY24 guidance for portfolio receipts falls short of expectations.
Intellectual PropertyPersistent uncertainty around the royalty for deuterated ivacaftor poses a risk for investors.
Revenue StreamsThe future of royalty income and patient switch rates for deuterated ivacaftor is unclear, impacting stock sentiment.
---
Ownership Overview
35.04% Insiders
23.17% Mutual Funds
30.35% Other Institutional Investors
11.44% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RPRX FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $25.35 and its highest was $33.66 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Currently, no data Available
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is Aug 07, 2024 which is in 79 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on May 09, 2024. The company reported $0.978 earnings per share for the quarter, missing the consensus estimate of $0.987 by -$0.009.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC pays a Quarterly dividend of $0.21 which represents an annual dividend yield of 2.97%. See more information on Royalty Pharma PLC dividends here
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is $0.97.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 450,981,020 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $0.978 in its last earnings report, missing expectations of $0.987. Following the earnings report the stock price went down -0.072%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Among the largest hedge funds holding Royalty Pharma PLC’s share is Viking Global Investors LP. It holds Royalty Pharma PLC’s shares valued at 283M.
---
Royalty Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.00 (79.68% Upside)
$49.00 (79.68% Upside)
Blogger Sentiment
Bullish
RPRX Sentiment 85%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.29%
12-Months-Change
Fundamentals
Return on Equity
12.84%
Trailing 12-Months
Asset Growth
-5.52%
Trailing 12-Months
Company Description
Royalty Pharma PLC
New York-based Royalty Pharma Plc is a biopharmaceutical company, which is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.
---
RPRX Company Deck
---
RPRX Earnings Call
Q1 2024
0:00 / 0:00
---
RPRX Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
---
RPRX Stock 12 Month Forecast
Average Price Target
$49.00
▲(79.68% Upside)
Technical Analysis
Best Analysts Covering RPRX
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-12.23%
reiterated a buy rating 3 months ago
Copying Chris Shibutani's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -12.23% per trade.
---